Pfizer Targets Generic Celebrex After Extending Patent

Law360, Los Angeles (March 5, 2013, 4:49 PM EST) -- Pfizer Inc. on Tuesday received an 18-month extension for its patent for the arthritis medication Celebrex, and promptly sued five drug companies for patent infringement for attempting to produce generic versions of the drug, the pharmaceutical giant said.

Pfizer sued generics makers Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Watson Laboratories Inc., Lupin Pharmaceuticals USA Inc. and Apotex Corp. in Virginia federal court on Tuesday for infringing U.S. Patent Number RE44048, Pfizer said in a statement.

The companies had previously filed abbreviated new drug applications with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.